Global prevalence of onychomycosis in general and special populations: An updated perspective
Mycoses · 2024-04 · 67 (4)
DOI: 10.1111/myc.13725 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Mycoses, online erschienen am 12.04.2024. Verfasst von Aditya K Gupta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Onychomycosis, Diabetes Mellitus, Kidney Transplantation. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Onychomycosis is a chronic nail disorder commonly seen by healthcare providers; toenail involvement in particular presents a treatment challenge.
Objective
To provide an updated estimate on the prevalence of toenail onychomycosis.
Methods
We conducted a literature search using PubMed, Embase and Web of Science. Studies reporting mycology‐confirmed diagnoses were included and stratified into (a) populations‐based studies, and studies that included (b) clinically un‐suspected and (c) clinically suspected patients.
Results
A total of 108 studies were included. Based on studies that examined clinically un‐suspected patients (i.e., with or without clinical features suggestive of onychomycosis), the pooled prevalence rate of toenail onychomycosis caused by dermatophytes was 4% (95% CI: 3–5) among the general population; special populations with a heightened risk include knee osteoarthritis patients (RR: 14.6 [95% CI: 13.0–16.5]), chronic venous disease patients (RR: 5.6 [95% CI: 3.7–8.1]), renal transplant patients (RR: 4.7 [95% CI: 3.3–6.5]), geriatric patients (RR: 4.7 [95% CI: 4.4–4.9]), HIV‐positive patients (RR: 3.7 [95% CI: 2.9–4.7]), lupus erythematosus patients (RR: 3.1 [95% CI: 1.2–6.3]), diabetic patients (RR: 2.8 [95% CI: 2.4–3.3]) and hemodialysis patients (RR: 2.8 [95% CI: 1.9–4.0]). The prevalence of onychomycosis in clinically suspected patients was significantly higher likely due to sampling bias. A high degree of variability was found in a limited number of population‐based studies indicating that certain pockets of the population may be more predisposed to onychomycosis. The diagnosis of non‐dermatophyte mould onychomycosis requires repeat sampling to rule out contaminants or commensal organisms; a significant difference was found between studies that performed single sampling versus repeat sampling. The advent of PCR diagnosis results in improved detection rates for dermatophytes compared to culture.
Conclusion
Onychomycosis is an underrecognized healthcare burden. Further population‐based studies using standardized PCR methods are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada.
- Mediprobe Research Inc., London, Ontario, Canada.
ORCID-Profile: Aditya K Gupta, Tong Wang, Shruthi Polla Ravi, Mary A Bamimore
Zitieren
APA
Gupta, A. K., Wang, T., Polla Ravi, S., Mann, A., & Bamimore, M. A. (2024). Global prevalence of onychomycosis in general and special populations: An updated perspective. Mycoses, 67(4). https://doi.org/10.1111/myc.13725
Vancouver
Gupta AK, Wang T, Polla Ravi S, Mann A, Bamimore MA. Global prevalence of onychomycosis in general and special populations: An updated perspective. Mycoses. 2024;67(4). doi:10.1111/myc.13725
BibTeX
@article{Gupta2024,
author = {Gupta, Aditya K and Wang, Tong and Polla Ravi, Shruthi and Mann, Avantika and Bamimore, Mary A},
title = {Global prevalence of onychomycosis in general and special populations: An updated perspective},
journal = {Mycoses},
year = {2024},
volume = {67},
number = {4},
doi = {10.1111/myc.13725}
}
EUVIMED